Close Menu

Sanofi

This week's news includes Illumina, Becton Dickinson, PerkinElmer, iGene Laboratory, Novacyt, Twist Bioscience, Lustgarten Foundation, and GlaxoSmithKline.

The researchers will combine genomic analysis with environmental and mobile device data from 1,200 participants to try to better understand the disease.

The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.

Linguamatics' I2E natural language processing engine helps Sanofi match HLA alleles with multiple sclerosis and associated drug treatments.

The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.

The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.

Berg will use its Interrogative Biology platform in order to assess potential biomarkers of seasonal influenza vaccination outcomes.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.